KRYSbenzinga

EC Grants Marketing Authorization To Krystal Biotech's VYJUVEK For Treatment Of Wounds In Patients With DEB Who Have Mutations In COL7A1 Gene, Starting From Birth

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 28, 2025 by benzinga